HER2 and miR-21 Detection in Breast Cancer Moves From Conventional Assays to Digital Platforms
Breast cancer diagnostics is entering a phase in which protein-level signaling and post-transcriptional regulation are being measured side by side rather than in isolation. In this hybrid systematic review and bibliometric mapping, HER2 and miR-21 emerge as complementary biomarkers with different biological meanings and different technical demands at the bench and in the clinic. HER2 reflects oncogenic signaling at the protein level, while miR-21 captures a layer of gene regulation that sits upstream and downstream of multiple malignant pathways. Together, they represent two ways of reading the same disease, one through membrane-associated receptor biology and the other through small non-coding RNA activity.
The clinical appeal is straightforward. Better detection can sharpen early diagnosis, improve prognostic stratification, and inform therapeutic decisions in a cancer type that remains a major cause of mortality and morbidity worldwide. The diagnostic gap is not simply about finding more biomarkers; it is about identifying markers that can be measured reliably, reproducibly, and at scale. In that setting, analytical performance becomes inseparable from clinical usefulness.
A 305-Study Corpus Maps the Field’s Technical and Scientific Core
The review followed PRISMA principles and searched the Web of Science Core Collection, PubMed, and Scopus before duplicate removal, screening, and eligibility assessment produced a final corpus of 305 publications. Bibliometric mapping with VOSviewer was then used to examine publication output, keyword co-occurrence, co-authorship, and institutional and country collaboration patterns. This design matters because it does more than summarize assay types; it shows how the field itself is organized, where methodological attention concentrates, and which regions are driving the literature.
The bibliometric signal points to a research area that has matured enough to develop recognizable clusters of inquiry. One cluster centers on conventional clinical techniques, another on newer detection platforms, and a third on translational questions around standardization and implementation. The molecular divide between HER2 and miR-21 also creates a technical divide: one biomarker is already embedded in clinical workflows, while the other still faces analytic and pre-analytic barriers that complicate routine adoption.
This is where the biology matters. HER2 testing has long been tied to treatment selection because receptor overexpression and amplification can identify tumors likely to respond to HER2-directed therapy. miR-21 occupies a different space, reflecting post-transcriptional dysregulation linked to cancer biology and potentially useful for prognosis, disease characterization, and future multiplex strategies. Their combined study suggests a move toward layered diagnostic models rather than single-marker decision-making.
Conventional HER2 Testing Still Anchors Clinical Practice
Conventional methods remain the clinical standard for HER2 assessment. In practice, that means established laboratory techniques continue to carry the weight of decision-making because they are familiar, interpretable, and already linked to therapeutic pathways. The review places these methods in their proper context: they are not obsolete, but they are increasingly being supplemented by newer technologies that promise greater analytical sensitivity and faster turnaround.
The reason is not hard to see. Traditional assays perform well when workflows are mature and quality control is stable, yet they can be limited by throughput, operator dependence, and the need for centralized infrastructure. In routine oncology, those constraints can slow diagnosis and delay treatment decisions. A biomarker with direct implications for therapy needs not only biological validity but also a diagnostic platform that can survive the realities of hospital laboratories.
For miR-21, the challenge is even sharper. MicroRNA measurement is technically more demanding than many protein assays because small RNA targets require careful handling and standardization across extraction, amplification, and normalization steps. Small differences in pre-analytic processing can alter results, which makes cross-study comparison difficult and slows clinical translation. The field has not lacked candidate methods; it has lacked uniformity.
Digital PCR and Biosensors Expand Sensitivity, Speed, and Miniaturization
Among emerging technologies, digital PCR stands out for sensitivity, while optical and electrochemical biosensors are attractive because they may support rapid and miniaturized testing. These platforms are being studied as complements to established diagnostics rather than wholesale replacements. Their main promise lies in detecting lower-abundance signals, reducing dependence on large laboratory infrastructure, and potentially enabling more scalable testing models.
The biological logic is compelling. If HER2 and miR-21 provide distinct windows into tumor behavior, then highly sensitive platforms can help capture signal that might otherwise be diluted in heterogeneous samples. Digital methods also suit the growing interest in precision oncology, where biomarker detection increasingly needs to support nuanced risk assessment and treatment planning. Yet analytical elegance is not enough; clinical validation still decides whether a method stays in the research setting or enters care pathways.
This review makes the central constraint plain. The new methods offer advantages in sensitivity, rapidity, and potential miniaturization, but implementation is limited by the lack of standardization and by the absence of large-scale validation. Without harmonized procedures, a highly sensitive test can still produce inconsistent results across laboratories, patient cohorts, or disease stages. In oncology diagnostics, reproducibility is not a technical footnote; it is the basis for clinical trust.
Asia Is Driving Publication Growth and Collaboration Density
The bibliometric map also reveals a geographic shift in publication output toward Asia, with China, India, and Iran showing high productivity and strong collaborative connectivity in the analyzed network. This is not merely a counting exercise. It suggests that the center of gravity for HER2 and miR-21 detection research is moving across institutions and countries that are building both output and connectivity at the same time.
Collaboration patterns matter because biomarker science depends on shared methods, shared cohorts, and comparable validation standards. When research activity becomes more networked, it can accelerate technical refinement, but it can also expose differences in assay selection and reporting practices. A field that spans protein assays, microRNA workflows, and hybrid diagnostic platforms needs common language before it can support routine clinical adoption.
The bibliometric results also reinforce the translational divide within the literature. Some studies are still focused on detection fundamentals, while others are attempting to bridge laboratory performance and clinical use. That split is visible in the publication network itself. The volume of work is rising, but the route from promising assay to validated tool remains uneven.
Standardization Remains the Bottleneck for MicroRNA Translation
The review closes on a familiar but unavoidable constraint: microRNA methods still need standardization, and emerging technologies still need clinical validation. For HER2, the path to clinical use is already established; for miR-21, the road is less direct and more method-dependent. The field is moving toward integrated precision oncology diagnostics, but the next step is not another isolated proof of concept. It is harmonized assay design, consistent reporting, and validation in larger real-world cohorts.
In practical terms, the future of breast cancer biomarker testing will likely depend on whether conventional and emerging platforms can be aligned rather than treated as competing camps. HER2 testing already informs patient care. miR-21 may eventually do the same, especially if detection technologies can meet the standards of reproducibility and scalability required in oncology practice. Until then, the literature points to promise without allowing premature certainty.